THE LYMPHOMA RESEARCH FOUNDATION 2022 ANNUAL REPORT
Every year, we are humbled to highlight the incredible progress made by the Lymphoma Research Foundation (LRF), which is only made possible through your generosity and belief in our mission to eradicate lymphoma and serve those touched by this disease.
As we reflect on 2022, we see a year in which our community and the Foundation were able to overcome challenges and make transformative progress. Still grappling with the impact of the COVID-19 pandemic, many patients and their caregivers relied upon the output of LRF’s COVID-19 and Lymphoma Panel. First convened in 2020 to inform the Foundation’s COVID-19 response, the Panel’s work has resulted in meaningful guidance and tangible patient programming, including our online COVID-19 Learning Center, which has become a critical tool for so many. Similarly, the LRF Helpline remains an important resource for the lymphoma community, serving more than 10,000 patients and caregivers last year alone.
Meghan Gutierrez Chief Executive Officer Steven Eichberg Chair, Board of DirectorsTo expand our reach further, the Foundation launched a Spanish-language version of its website as a complement to its expert patient education resources through our Health Equity Initiative. And recognizing that patients learn in different ways and are increasingly using mobile health technology to manage their health, we were thrilled to release an updated version of our award-winning mobile app, Focus on Lymphoma.
The Foundation continues to fund a robust portfolio of cutting-edge research across every lymphoma subtype, and in 2022 LRF funded 29 research grants totaling nearly $6 million. This year’s report details our many grantees and the critical projects that would not be possible without your generous support.
In partnership with our expert Scientific Advisory Board, the Foundation was also able to harness its convening power to address important areas of unmet need. Through the preeminent Jaime Peykoff Follicular Lymphoma Initiative, LRF convened a first-of-its-kind scientific workshop to present data regarding newly approved and emerging treatments and discuss the best approaches for designing clinical trials and new therapeutic regimens. LRF also gathered a slate of international experts for its second Adolescent and Young Adult (AYA) Lymphoma Consortium and Scientific Workshop, continuing to lead the way in the investigation of those lymphomas which disproportionately impact young people. While much work remains, your partnership and dedication propel us into the new year. We remain as dedicated as ever to our shared goals and service to the more than one million Americans living with and surviving lymphoma.
Yours in partnership and progress,
Steven Eichberg Chair, Board of Directors
Meghan Gutierrez Chief Executive Officer
STEVEN EICHBERG
Chair
Plymouth, MA
JEFF BLOCK
Vice Chair and Treasurer San Francisco, CA
KIM METCALF
Vice Chair
Landenberg, PA
LEIGH OLSON Secretary
Miami Beach, FL
MICHAEL AKINYELE
Upper Marlboro, MD
MICHAEL FROY
Chicago, IL
HARRIET GREENBERG
New York, NY
JOHN LEONARD, MD
Past Chair, Scientific Advisory Board
New York, NY
BOB MCAULEY
Charlottesville, VA
JOHN A. NELSON
Westport, CT
SCOTT PANSKY
Tarzana, CA
DIANE PARKS
Carbondale, CO
JOEL POLLICK
Brooklyn, NY
STEVEN J. PRINCE
Past Chair
Purchase, NY
KEVIN SHEA
Naples, FL
SONALI M. SMITH, MD, FASCO Chair, Scientific Advisory Board
Chicago, IL
MICHAEL WERNER Immediate Past Chair
Chicago, IL
MEMBERS EMERITUS
MORTON COLEMAN, MD New York, NY
ERROL M. COOK
Past Chair
Boca Raton, FL
In Memoriam
BARBARA FREUNDLICH
Founder
New York, NY
JERRY FREUNDLICH
Founder and Past Chair
New York, NY
TOM GOLDSTONE
New York, NY
DONNA REINBOLT
Houston, TX
ROBERT WERNER
Aventura, FL
MARTHA CRAWFORD
Santa Fe, NM
MARK DENNISH
Plymouth, MA
AMY KIMBALL
Easton, MD
LEWIS KWEIT Long Island, NY
KATHRYN MCGILL
Dallas, TX
JACKIE QUAN Washington, DC
ADWIN SPRINGER
London, Ontario, Canada
LYNDSAY SPRINGER
Washington, DC
GARY TURKISH
Hilton Head, SC
SONALI M. SMITH, MD, FASCO Chair
The University of Chicago
ANN S. LACASCE, MD, MMSc Chair-Elect
Harvard Medical School Dana-Farber Cancer Institute
RANJANA ADVANI, MD Stanford University School of Medicine
ASH A. ALIZADEH, MD, PhD Stanford University School of Medicine
STEPHEN ANSELL, MD, PhD Mayo Clinic, Rochester
KRISTIE A. BLUM, MD
Winship Cancer Institute of Emory University
JENNIFER BROWN, MD
Dana-Farber Cancer Institute
JAMES CERHAN, MD, PhD Mayo Clinic, Rochester
ETHEL CESARMAN, MD, PhD
NewYork-Presbyterian Hospital
Weill Cornell Medicine
BRUCE D. CHESON, MD, FACP
Past Chair, 2010-2012
The Center for Cancer and Blood Disorders
SANDEEP DAVE, MD, MS Duke University
KIERON M. DUNLEAVY, MD Georgetown Lombardi Comprehensive Cancer Center
KOJO S.J. ELENITOBA-JOHNSON, MD Memorial Sloan Kettering Cancer Center
ANDREW M. EVENS, DO, MSc, FACP Rutgers Cancer Institute of New Jersey
CHRISTOPHER R. FLOWERS, MD, MS
The University of Texas MD Anderson Cancer Center
JONATHAN W. FRIEDBERG, MD, MMSc
University of Rochester
James P. Wilmot Cancer Institute
LEO I. GORDON, MD, FACP
Past Chair, 2015-2017
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
MICHAEL GREEN, PhD The University of Texas MD Anderson Cancer Center
THOMAS M. HABERMANN, MD Past Chair, 2017-2019 Mayo Clinic, Rochester
STEVEN M. HORWITZ, MD Memorial Sloan Kettering Cancer Center
ERIC D. HSI, MD Wake Forest
BRAD S. KAHL, MD Washington University School of Medicine
KARA KELLY, MD Roswell Park Comprehensive Cancer Center University at Buffalo Jacobs School of Medicine and Biomedical Sciences
JOHN P. LEONARD, MD Past Chair, 2012-2015 NewYork-Presbyterian Hospital Weill Cornell Medicine
BRIAN K. LINK, MD University of Iowa
IZIDORE S. LOSSOS, MD University of Miami Health System Sylvester Comprehensive Cancer Center
PETER MARTIN, MD NewYork-Presbyterian Hospital Weill Cornell Medical Center
ARI MELNICK, MD NewYork-Presbyterian Hospital Weill Cornell Medicine
LINDSAY MORTON, PhD National Cancer Institute
LORETTA NASTOUPIL, MD The University of Texas MD Anderson Cancer Center
TERESA PALOMERO, PhD Institute for Cancer Genetics, Columbia University
LAURA PASQUALUCCI, MD Institute for Cancer Genetics, Columbia University
BARBARA PRO, MD Columbia University
H. Irving Comprehensive Cancer Center
LISA RIMSZA, MD Mayo Clinic, Arizona
LISA GIULINO ROTH, MD Weill Cornell Medicine
KERRY J. SAVAGE, MD BC Cancer, Vancouver
DAVID W. SCOTT, MBChB, PhD BC Cancer, Vancouver
LAURIE SEHN, MD, MPH BC Cancer, Vancouver
MARGARET SHIPP, MD
Harvard Medical School
Dana-Farber Cancer Institute
EDUARDO M. SOTOMAYOR, MD Tampa General Hospital
CHRISTIAN STEIDL, MD BC Cancer, Vancouver
JOHN M. TIMMERMAN, MD UCLA Jonsson Comprehensive Cancer Center
SVEN de VOS, MD, PhD
UCLA Jonsson Comprehensive Cancer Center
HANS-GUIDO WENDEL, MD Memorial Sloan Kettering Cancer Center
ANDREW D. ZELENETZ, MD, PhD
Immediate Past Chair, 2019-2021 Memorial Sloan Kettering Cancer Center
MEMBERS EMERITUS
MORTON COLEMAN, MD NewYork-Presbyterian Hospital Weill Cornell Medicine
KANTI R. RAI, MD Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
MICHAEL E. WILLIAMS, MD, ScM University of Virginia Cancer Center
The Lymphoma Research Foundation (LRF) announced its 2022 grant class in April: 29 research grants awarded to scientists based at many of the world’s leading cancer research institutions, totaling nearly $6 million in innovative lymphoma and chronic lymphocytic leukemia (CLL) research. LRF maintains a strong commitment to supporting early career investigators, ensuring they can build a successful career in the field of lymphoma research.
This commitment is illustrated in the more than one dozen grants awarded to early career investigators in 2022 alone. They include four dynamic Clinical Investigator Career Development Awards (CDAs), which support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools. Also included are eight Postdoctoral Fellowship Grants, designed to support investigators at the level of advanced fellow or postdoctoral researcher in laboratory or clinic-based research with results and conclusions that must be relevant to the treatment, diagnosis, or prevention of lymphoma.
“The benefits of early career awards include ensuring that scientists obtain a depth of knowledge in a field like lymphoma, which otherwise proves difficult—if not impossible—to pursue mid-career or later,” said LRF Chief Executive Officer Meghan Gutierrez. “As public funding for such grants decreases and therefore becomes more competitive, the need for private foundations and the support of our partners is more critical than ever before.”
The LRF Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma and CLL research, whether in the lab or in the clinic. The primary goal of the LSRMP is to retain its talented participants—called LRF Scholars—in the field of lymphoma by providing mentoring and education programming and fostering research collaboration among expert faculty and grantees. Led by the 2022 LSRMP Clinical Research co-chairs Steven Horwitz, MD (Memorial Sloan Kettering Cancer Center), and Kami Maddocks, MD (The Ohio State University Comprehensive Cancer Center); and Laboratory/Translational Research co-chairs Ari Melnick, MD (Weill Cornell Medicine), Christian Steidl, MD (BC Cancer, Vancouver), and Laura Pasqualucci, MD (Columbia University), the new class boasts translational and clinical researchers pursuing a diverse range of research projects with a goal to improve patient outcomes.
Peykoff Initiative Investigator
MILLER SCHOOL OF MEDICINE OF THE UNIVERSITY OF MIAMI
Research Study: Loncastuximab Tesirine in Patients with Relapsed or Refractory Follicular Lymphoma
Lymphoma Focus: B-cell lymphomas, indolent non-Hodgkin lymphoma
MEMORIAL SLOAN KETTERING CANCER CENTER
Research Study: Enasidenib for IDH2-Mutated
Angioimmunoblastic T-cell Lymphoma
Lymphoma Focus: T-cell lymphomas
Peykoff Initiative Investigator
MEMORIAL SLOAN KETTERING CANCER CENTER
Research Study: Mosunetuzumab for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma
Lymphoma Focus: Indolent non-Hodgkin lymphoma, B-cell lymphomas
BOYU HU, MD
Health Equity Initiative
THE UNIVERSITY OF UTAH
Research Study: Targeting DNA Damage Repair
Pathways in Relapsed/Refractory Chronic Lymphocytic Leukemia
Lymphoma Focus: B-cell lymphomas, chronic lymphocytic leukemia (CLL)
TOMOHIRO AOKI, MD, PHD
Health Equity Initiative
BC CANCER
Research Study: Treatment Failure in Hodgkin
Lymphoma: Correlates with Genetic Mutations and Tumor Microenvironment
Lymphoma Focus: Hodgkin lymphoma, B-cell lymphomas
UNIVERSITY OF PENNSYLVANIA, PERELMAN SCHOOL OF MEDICINE
Research Study: Precision Targeting of Non-Hodgkin
Lymphomas Using CAR T Cells Directed Toward the B-Cell Receptor
Lymphoma Focus: Aggressive non-Hodgkin lymphoma, B-cell lymphomas, chronic lymphocytic leukemia (CLL)
COLUMBIA UNIVERSITY
Research Study: Identifying Pathogenetic Markers for Therapy-Refractory Burkitt Lymphoma
Lymphoma Focus: Aggressive non-Hodgkin lymphoma, B-cell lymphomas, adolescent/young adult lymphoma, pediatric lymphoma
ANTONIO FERREIRA,
Condon Family Fellow
BRIGHAM AND WOMEN’S HOSPITAL
Research Study: The Follicular Lymphoma Stromal Cell Microenvironment
Lymphoma Focus: Indolent non-Hodgkin lymphoma, B-cell lymphomas
UNIVERSITY OF PENNSYLVANIA, PERELMAN SCHOOL OF MEDICINE
Research Study: Oncogenic Role of NPM1-TYK2 in T-Cell lymphoma
Lymphoma Focus: T-cell Lymphomas
THE UNIVERSITY OF TEXAS
MD ANDERSON CANCER CENTER
Research Study: CD38 as a Targetable Antigen in Large B-Cell Lymphoma
Combined with CD19 CAR T Cells
Lymphoma Focus: B-cell lymphomas
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Research Study: Elucidating the Role of ZNF608 In B-Cell Non-Hodgkin Lymphoma
Lymphoma Focus: Indolent non-Hodgkin lymphoma, B-cell lymphomas
RAN XU, PHD
Dr. Oliver Press Memorial Fellow
DANA-FARBER CANCER INSTITUTE
Research Study: Interrogating Extremely Rare MRD in Mantle Cell Lymphoma Treated With CAR T-Cells
Lymphoma Focus: B-cell lymphomas
The Lymphoma Research Foundation (LRF) also funded the inaugural Follicular Lymphoma Priority Research grants in 2022, through the LRF Jaime Peykoff Follicular Lymphoma Initiative. Established in 2020 through a new partnership with the Peykoff Family and Niagara Cares, the $10 million Initiative is poised to transform the follicular lymphoma (FL) treatment landscape for tens of thousands of patients by harnessing the Foundation’s unique resources, convening the world’s experts in FL research and patient care, and driving direct investment in clinical research. An additional five grants will be awarded in 2023.
STEPHEN ANSELL, MD, PHD
Peykoff Initiative Investigator
MAYO CLINIC, ROCHESTER
Research Study: The Immunological Phenotype of Intratumoral T-cells in Follicular Lymphoma
Lymphoma Focus: Non-Hodgkin B-cell lymphoma, follicular lymphoma
TODD FEHNIGER, MD, PHD
Peykoff Initiative Investigator
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Research Study: NK Cell Biology and Therapy for Follicular Lymphoma
Lymphoma Focus: Non-Hodgkin lymphoma, follicular lymphoma
ABNER LOUISSAINT, MD, PHD
Peykoff Initiative Investigator
MASSACHUSETTS GENERAL HOSPITAL
Research Study: Interplay of Microenvironment and Epigenetics in a Novel Model of FL
Lymphoma Focus: Non-Hodgkin lymphoma, B-cell lymphomas, follicular lymphoma
DAVID SCOTT, MBCHB, PHD
Peykoff Initiative Investigator
BC CANCER
Research Study: Four-Dimensional Characterization of FL to Predict Clinical Trajectory
Lymphoma Focus: Non-Hodgkin lymphoma, B-cell lymphomas, follicular lymphoma
HANS GUIDO WENDEL, MD
Peykoff Initiative Investigator
MEMORIAL SLOAN KETTERING CANCER CENTER
Research Study: Understanding and Therapeutically Targeting Epigenetic Drivers of Oncogenesis and Immune Evasion in FL
Lymphoma Focus: Non-Hodgkin lymphoma, B-cell lymphomas, follicular lymphoma
PARTNERSHIPS:
LRF donors and supporters hit the links at Quaker Ridge Golf Club in Scarsdale, New York, on May 23 for LRF’s 10th Annual Golf Invitational. Golfers had the chance to test their skills at this famed course, which has hosted three Met Opens, three Met Amateurs, and three Met PGA Championships. In addition, 2018 Curtis Cup Match was the second USGA championship hosted there. While guests enjoyed the pristine course, they raised over $335,000 for LRF’s mission. This annual event is chaired by longtime LRF supporters Steve Prince, who is also a member of the LRF Board of Directors, and Jim Stern.
Over 200 guests gathered in Chicago on June 2, for LRF’s Swirl: Chicago Wine Tasting Event, where they raised more than $90,000. Guests tasted a curated selection of Italian wines from Southern Glazer’s Wine & Spirits, a key partner and wine sponsor of the Swirl series. Attendees also sampled delicious bites as they bid on fabulous prizes offered in the silent auction, all in support of the LRF mission to eradicate lymphoma.
LRF was thrilled to return to New York City for its 2022 LRF Annual Gala. The Gala is a special evening celebrating advancements made in lymphoma research and patient care as well as the visionaries, researchers, and advocates who make them possible. The 2022 Gala honored Steven M. Horwitz, MD, with the Distinguished Leadership Award, and Pfizer with the Corporate Leadership Award. Chaired by Madhvi and Ramesh Subrahmanian, this year’s program brought together key leaders from the lymphoma community, including esteemed members of LRF’s Scientific Advisory Board and Board of Directors, representatives from oncology industry partners, healthcare providers, patients, caregivers, and highimpact supporters from throughout the country. Attendees gathered to celebrate all we accomplished together over the past year and to ensure that LRF may continue to pursue its vital mission. A special message from Academy Award®–winning actor and lymphoma survivor Jeff Bridges provided an especially poignant moment during the first in-person gala the Foundation was able to hold since the beginning of the pandemic.
Lymphoma Research Foundation (LRF) distinguished events provide opportunities for members of the lymphoma community and their friends to support innovative research and patient care by attending and sponsoring unique events across the country! Here are just a few examples of events that propelled LRF’s work in 2022.
Facilitating collaboration and partnerships among academic scientists, clinicians, government, regulatory agencies, and patients is a critical component of the Foundation’s work. Through its global lymphoma consortia, research initiatives, and scientific workshops, the Lymphoma Research Foundation (LRF) mobilizes the research community to overcome systemic challenges and expedite the development of treatments. In 2022, LRF used its convening power to explore two important areas of scientific discovery and unmet need: follicular lymphoma (FL), and adolescent and young adult (AYA) lymphoma.
FL is an indolent form of non-Hodgkin lymphoma that remains incurable. Although patients have high response rates to therapy, most will develop increasingly resistant disease and some will transform into an aggressive disease. Recent clinical trials have provided insight into the efficacy and safety of various therapies, yet aligning treatment with the disease biology and treatment sequencing remain key clinical challenges. Several novel agents are also being developed, based on significant LRF investments in FL research. To build upon this important work, LRF held its inaugural International FL Scientific Workshop in April, where experts from around the world convened to discuss the current standard of care, highlight unmet patient needs, present data regarding newly approved and emerging agents, and discuss the best approaches for designing clinical trials and new treatment regimens. The 2022 International FL Scientific Workshop was funded through the LRF Jaime Peykoff Follicular Lymphoma Initiative. The Foundation will publish a summary of the workshop, which will review recent research findings and highlight potential areas for future study, serving as a roadmap for the global FL research community. LRF will convene a follow-up workshop in 2024 to continue to propel the field of FL research forward.
On June 23 and 24, LRF convened physicians and scientists from more than 40 academic and medical institutions, federal agencies, and pharmaceutical companies for its second AYA Lymphoma Consortium Scientific Workshop.
LRF initially launched a multifaceted AYA initiative in 2014 with its founding partner, The Paul Foundation, to assist young lymphoma patients in addressing the medical challenges, psychosocial needs, and access issues they may encounter. The overwhelmingly positive response to this initiative led LRF to establish a first-ofits-kind AYA Lymphoma Consortium. The chief objective of the AYA Lymphoma Consortium is to advance the study of AYA lymphomas and improve treatments and care for this patient population, from the point of diagnosis through long-term survivorship.
Both LRF and the physicians who treat adult and pediatric lymphoma believe lymphoma in AYAs warrants special attention, as research suggests that lymphoma-related death occurs more often in the AYA group than in younger children and older adults. The underlying reasons are complex, as they are numerous, driven by biology, etiology, treatment patterns, and as social factors. Additionally, factors like the transition from pediatric to adult care and changes in access that come with changing jobs are unique challenges facing young adults transitioning to adulthood. The Foundation seeks to publish key findings from the workshop as well as from the first-of-its-kind AYA Lymphoma Consortium.
Thousands of people across the country turn their talents and interests into unique fundraising events to support the Lymphoma Research Foundation (LRF) mission. Whether they attended a Lymphoma Walk, participated in a marathon or road race, or created a new event, LRF’s partners, generous donors, and volunteers helped to make 2022 a successful year for Team LRF!
On May 1, during this year’s TD Five Boro Bike Tour, 32,000 cyclists took to the streets of New York City—including members of Team LRF! This annual event, America’s largest bike ride, offers riders the chance to enjoy 40 miles of car-free streets through all five of New York’s boroughs. For this year’s ride, LRF teammates raised thousands of dollars. Congratulations to our top Team LRF rider, Matt Silbermann!
Over 1,000 participants and volunteers gathered in Minnesota, Chicago, Dallas, and Phoenix in 2022 to raise over a half million dollars at local Lymphoma Walks. Speakers and LRF grantees, including Dr. Kathleen Dixon from the University of Minnesota, Dr. Adam DuVall from The University of Chicago, and Dr. Adam Lin from Northwestern University, cheered on and encouraged participants, highlighting the importance of lymphoma research and the impact their fundraising has on the critical research powered by LRF.
After losing his mother to lymphoma, Dan Anderson gathered seven friends to create LRF Team Tri as a way of honoring his mother’s memory and spreading awareness for the need for lymphoma research funding. The group, based out of Gainesville, Florida, planned to participate in triathlons across the country in 2022, with the ultimate goal of qualifying for the 2022 Ironman World Championship in Hawaii while also raising $50,000 for LRF. Dan qualified for the World Championship during the first qualifying race of the season, Ironman Florida!
Members of the LRF community were among the 26,000 runners who participated in the 40th anniversary Medtronic Twin Cities Marathon on October 2. Seven runners representing Team LRF raised more than $7,500, including Georgia, who completed her first 10-mile race to honor her father; and Emily, who ran the full marathon in honor of her grandfather.
A diagnosis of lymphoma or chronic lymphocytic leukemia (CLL) can bring about many different emotions and numerous questions, whether you are newly diagnosed or seeking help with long-term survivorship. The Foundation offers a wide range of support services for people with lymphoma and their loved ones, through the Lymphoma Research Foundation (LRF) Helpline. In 2022, trained Helpline staff provided individualized information on types of lymphoma, diagnostic tests, treatment options, potential side effects, and the latest in research to more than 10,000 patients and caregivers..
Throughout the past year and the entire pandemic, Helpline staff members provided a range of free services, including providing patients and caregivers with a list of questions to ask their healthcare team and conducting customized clinical trial searches through the LRF Clinical Trials Information Service. Through the Lymphoma Support Network that has a membership of over 7,000, both patients and caregivers were connected with others who have gone through a similar experience. Patients and caregivers were also connected with financial assistance resources and other referrals for existing unmet medical and financial needs.
Mobile health technology is becoming an increasingly popular way to empower patients to take charge of their health by offering an easy way to track symptoms, record appointments, log lab results, and access educational resources. LRF has been leading the way in mobile health technology since the launch of its first-of-its-kind mobile app, Focus on Lymphoma, in 2013. The award-winning app was designed to help patients and caregivers better understand and manage their disease through comprehensive information tailored to the user’s specific lymphoma subtype. It provides tools to help users record/take notes during doctor sessions and track medications, blood results, and symptoms. Building upon the success of Focus on Lymphoma, LRF updated its app this fall, providing a new look and enhanced tools to manage a lymphoma diagnosis. The new update makes it easier for app users to access their information securely across multiple devices through login capabilities and integration with Google. It also features several valuable tools, including a medication tracker, which provides a seamless way for users to track prescriptions through integration with the Food and Drug Administration’s (FDA) National Drug Code Directory, and individualized support through a direct connection to the LRF Helpline.
This February, LRF supporters came together to show their love for lymphoma patients by raising $61,000 as part of the Foundation’s annual Show Your Love campaign. The funds raised help to power LRF’s Patient Aid Grant program, which is funded entirely by individual donors and provides critical assistance to patients struggling with financial toxicity caused by costs related to cancer care. This year’s gifts were made even more impactful when they were matched by a generous group of LRF donors, helping twice as many lymphoma patients offset costs related to their treatment, ensuring no patient has to choose between paying for basic necessities or receiving life-saving care.
On June 5, LRF celebrated lymphoma survivors and thrivers as part of National Cancer Survivors Day (NCSD). Our community joined us in celebration by raising over $12,000 to aid with cutting-edge research and critical resources for survivors and patients. This year, we also saw LRF donors becoming champions for survivors by starting their own NCSD fundraising campaigns using our peer-to-peer fundraising platform.
LRF’s patient support and education programs, in addition to the Early Career Research Grant program, are all made possible by donations from private supporters. When you give to the LRF, you are investing in the most promising research that has the greatest potential to improve the lives of those impacted by lymphoma, dramatically.
LRF was proud to establish the Kanti R. Rai, MD Clinical Scholar program for CLL research, in 2022, in recognition of Dr. Rai’s global leadership in the field and his commitment to LRF’s mission. Dr. Kanti Rai has been a global leader in the field of chronic lymphocytic leukemia (CLL) research for more than four decades. Elected to the LRF Scientific Advisory Board in 2007, Dr. Rai has helped to shape the LRF’s research portfolio and mentor the next generation of CLL clinicians and scientists. More than $650,000 has been raised in Dr. Rai’s name since announcing this initiative.
Through special campaigns, the Lymphoma Research Foundation’s (LRF) monthly giving program Circle of Hope, and direct or planned gifts, donors partner with LRF to invest in research that has the greatest potential to advance cures for lymphoma and provide support to those impacted by a diagnosis.
Due to the rapid advancement and tremendous progress made in the study of lymphoma, the Lymphoma Research Foundation (LRF) offers a wide range of educational programs and publications for people with lymphoma and their loved ones. The programs feature expert speaking faculty and provide information about every lymphoma subtype, treatment options, supportive care as well as long-term survivorship. Programs for healthcare professionals create a unique opportunity for learning and collaboration.
Despite the COVID-19 pandemic, there was no interruption in LRF’s commitment to providing up-to-date patient education for people with lymphoma and their loved ones, in 2022. While in-person events were postponed, the Foundation used digital platforms to deliver virtual education programs around the country, including Virtual Ask the Doctor About Lymphoma programs, Lymphoma Workshops, and the North American Educational Forum on Lymphoma. Each program also addressed ongoing concerns regarding COVID-19 that were top of mind for patients. These programs all feature specialized plenary and breakout sessions and may be viewed as archived programs on the LRF website.
In addition, LRF debuted a new suite of materials and programming in Spanish language. Cancer is the leading cause of death among Hispanics/Latinos, who represent the largest racial/ethnic minority group in the United States. The new materials included print, digital, and live programs, combining LRF’s lymphoma/chronic lymphocytic leukemia (CLL) expertise, cultural awareness, and expertly translated materials. In addition, the Foundation launched a new Spanish-language version of its website to include comprehensive information on clinical trials (lymphoma.org/es). The new publications are accessible on the new website as well as lymphoma.org and are available to order free of charge via the LRF Helpline. The live education programs were led by bilingual lymphoma experts and featured interactive components to help meet the specific needs of attendees, a hallmark of all LRF education programs.
Throughout the year, the Lymphoma Rounds program provided a forum for practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians network, share best practices, and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts. In 2022, 19 Lymphoma Rounds programs were held, and 66 institutions presented a total of 63 case presentations through the series.
The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2022 and 2021 have been derived from Lymphoma Research Foundation’s audited financial statements. The Lymphoma Research Foundation’s complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation’s website, lymphoma.org/annualreport. The Financial Statements ended June 30,2022 have been audited by BDO USA, LLP.
The progress made by the Lymphoma Research Foundation in 2022 was made possible by its many supporters—patients, survivors, caregivers, family members, scientists, clinicians, nurses, communities, and companies—who recognize that partnership is critical to advancing innovative lymphoma research and the development of essential patient education programs. Thank you for your belief in the Foundation and our shared mission to eradicate this disease forever.
Thank you to our leadership donors for providing hope to the lymphoma community through their commitment to supporting innovative research and evidence-based educational resources.
2seventy bio
AbbVie Inc.
Acrotech Biopharma, LLC
ADC Therapeutics
Nina & Walter J. Andrews
Steven & Marilyn Aronow
AstraZeneca Pharmaceuticals, LP
David & Patricia Atkinson
The David R. and Patricia D. Atkinson
Foundation
John C. Balan Living Trust
John W. Ballantine
Baranay Family Foundation
Gerald & Mary Ellen Batzner
Bayer Family Foundation
Michael & Lana Beaury
BeiGene USA, Inc.
Maxa Schutzbank Berid, Esq.
Debra Bernstein
Biotechnology Innovation Organization (BIO)
Jeffrey A. Block
Edward & Eileen Bradbury
Bristol-Myers Squibb
Robert & Arlette Britton
The Bruning Foundation
BTG International Inc.
Connie Bull
Dr. Bruce & Christine Cheson
Clearfield Capital Management LP
Clint Coghill
Michael & Patty Cohen
Stacey Cohen
Ms. Jeannie R. Colbert
Susan & James Colletti
The Condon Family
Errol & Gladys Cook
Toby & Leon Cooperman
CRISPR Therapeutics, Inc.
Daiichi Sankyo, Inc.
Gary S. Davis
Estate of Audrey DePasquale
Laura & Foster De Reitzes
Dirschl Family Trust
Lawrence D. & Gail Dobosh
Dubose & Dorothy Heyward Memorial Fund
Steven & Jean Eichberg
Jennifer Englander
Epizyme, Inc.
Robert Feilbogen
Jeff Fellinge
The Ferriday Fund Charitable Trust
Arlene Fischer
Norman J. & Doris Fisher Foundation
Foundation Medicine, Inc.
Roberta Franklin
Jerry & Barbara Freundlich
Friedman LLP (now Marcum LLP)
Michael & Lynn Froy
Nathan Gantcher
Robert J. Gardner
Genentech
Genmab US, Inc.
Deborah L. Gersh
George & Margie Gey
James & Joyce Giles
Nancy Goldman
Tom & Jenn Goldstone
Robert Goodman
Christopher Gorelik
Grassfield High School
Jake Greenberg
Scott & Harriet Greenberg
Dr. & Mrs. Thomas & Mary Jo Habermann
Richard & Tracy Hazan
Hearthland Embers Fund
Hexameter Capital Management
Helen Hidley
Gary & Diane Hirsch
Robert A. Horne
Dr. Steven M. & Nicole Horwitz
Incyte Corporation
Johnson & Johnson Family Companies
Katherine Johnson
Karyopharm Therapeutics, Inc.
Barrie & Glen Kassan
Thomas L. Kempner
Lawrence Kestin
Kite Pharma Inc.
William & Carolyn Klein
Knight Family Charitable Foundation
Jahanna M. Knight
Jeffrey & Terri Krasnoff
Andrew & Elizabeth Kriegman
The G. Dewey & Mary J. Krumrine Foundation
Sheila F. & Myron W. Kronisch Charitable Trust
Andrew & Mara Kupferberg
Lowell Kwiat
Kyowa Kirin, Inc.
Sidney & Ruth Lapidus
Barry & Ilyse Leibowitz
Arnold & Deborah Lerman
Le-Vel Brands, LLC.
Leslie Levine
Dr. & Mrs. Michael S. Levine
Lilly USA, LLC
Evelyn & John Lipori
Sandra Lundquist
Paul V. Majkowski
Mallinckrodt Pharmaceuticals
The Mann Charitable Foundation
Bernard & Billi Marcus
Mattress Firm, Inc.
Robert & Laura McAuley
Devon McGoldrick
Memorial Sloan Kettering Cancer Center
Thomas G. Mendell
Eric & Debbi Mendelson
Bruce & Phipps Menk
Merck & Co., Inc.
David & Barbara Messer
Kimberly Metcalf
Joel & Charlene Meyer
Christine Monterosso
MorphoSys US Inc.
Eugene & Mary Murphy
John A. Nelson
Bonni & Kenneth Newton
Novartis Pharmaceuticals Corp.
Owen A. O’Connor
Leigh & Cory Olson
ONO Pharma
Parks Family Endowment Fund
Joseph E. Parzick
Steve & Anne Pellegrini
Pfizer Inc
Miriam & David Phalen
Pharmacyclics
Richard & Joann Philips
PhRMA
Pisani Family Foundation
PleXus Communications
Andrew W. Potash
Mr. & Mrs. Steven J. Prince
Robert & Tracey Pruzan
Mary Purcell
Stoney T. Quinto, Sr. Estate
Anthony Ragucci
Regeneron Pharmaceuticals, Inc.
Mike Repole
Richard Cramer Family Charitable Fund
Patrick J. & Judy Riordan
David Ritter
Pat & Glenda Rogers
The Rosen Family
Jerald E. & Lois Rosenblum
James & Sheri Rosenfeld
Michele K. Ross
Dawn Rossano
Eric & Laurie Roth
Anne D. Rubin
David B. Rubin
Robert M. Rubin
Runge Lymphoma Project
Rutgers Cancer Institute of New Jersey
Roy Ryan
Maureen Sabatella
Gregory E. Sacco
Brad & Lesley Sarnoff
Mona Sarnoff
Norton & Elaine Sarnoff
Roberta Sarnoff
Edward Schwartz
Seagen
Secura Bio
Thomas & Donna Seith
Lance Shackway
Kevin & Kimberly Shea
Sigma Nu (University of Oregon)
SPIRE Credit Union
Chike Springer Foundation
The Starr Foundation
Starwood Property Trust
Jeffrey Stedman
Richard N. Steegstra
Jane & James A. Stern
Barbara Stone
Sandra L. Stone
Steven Stone
Mayo & Elizabeth Stuntz
Ramesh & Madhvi Subrahmanian
Susan & Jeffrey Sussman
Gene & Tracy Sykes
Michael B. Targoff
Lisa A. Taverna
Laura Tepper
TG Therapeutics, Inc.
The Jerome and Elaine Nerenberg Foundation
Ira & Nan Theodore
Gaylord & Diane Thormodsgard
Thomas N. Tryforos
The University of Chicago Medical Center
Dr. Craig Vosburg
Michael & Laura Werner
Robert I. Werner
Bruce W. Wetzel
Sharon Wickes
Michael & Rebecca Williams
Aletta Wilson
Elizabeth Winslow
Janet L. Winter
Penny D. Wolf
Tracy Wolniewicz
Bruce & Andrea Yablon
Yablan Family Foundation
Adelaide & John Zabriskie
Dr. Gianna Zuccotti & Dr. David Weinstock
Mr. & Mrs. Kurt Zumwalt
Thank you to our Circle of Hope partners, whose monthly support ensures we can respond to the needs of our community and invest in further groundbreaking research year-round.
Ileen Akers
Jason Albano
Gary & Barbara Anthony
Angela M. Baglione
Micah & Olga Banner
Ray L. Baumler
Kaethe Bierbach
Tony Blanco
Christine M. Bolanis
Barbara Bornstein
Mary Brady
Arlene R. Bruskin
Steven Chudnick
Erwin & Patricia Cohen
Mary R. Coleman
Frances Collazo
Andrew & Michelle Dahl
Toby Davidow
Michael Dejoy
Peter De Lijser
Victoria Dillon
Carolyn Dobson
Shannon Dorsey
Kenneth P. Ducote
Susana Enriquez
Frank C. Famiano
Dennis & Debbie Ferguson
Lorraine Ferrara
Theresa Fillinger
Juliana Fuller
Luther & Dorothy Gales
Cynthia Gargagliano
Margaret A. Ghering
John Greabe & Martha Madsen
Robert & Lesley Nan Haberman
Gerry & Jeanne Hall
Richard Hammett
Sue Hammond
Elizabeth Haughie
Joshuah Hernandez
Judy Herriman
Judith & Francis Higgins
Rick Hind
Rosalie Hish
Ajay Kalra
Jessica Kern
Mary K. King
Christopher Kinsler
Michael & Susan Poll Klaessy
Aaron Krause
Label LLC
Ron Laughlin
Anna Lazzaro
Kate LeBoeuf & Robert Sheehan
Richard & Michelle Lebreux
Erica Lecce
Julia Levitz
Casey Lipscomb
Larry Loose
Ira & Lois Lunsk
Celia Maldonado
Dr. Blase Masini
Monica Mertilus
Shaw Miseyko
Kian Javadi Namin
Sharyn A. Novotny
John O’Rourke
Marilyn Paskert
Jamie Pawelek
Thomas Peele
Don Pendergrass
Benjamin & Elizabeth A. Pickett
Alexis Pierce
Rebecca A. Pimentel
Erin Poole & David Gooch
Arthur & Deborah Price
Angela Reel
Tanya Rhodes
James E. Rodgers
Lauren Roland
Mark Salandra
Mark Sauerwald
David Smith
Donna St. George
Sheila Stamper & Roger Smith
Rod Stoner
Danielle Surra
Vincent S. Talerico
Isaac Thomas
Michael & Kristin M. Timmons
Minh-Quan Tran
Alicia Turner
Loren & Sharon Volk
Daniel & Laura Wallenstein
Bruce & Sandra Wells
Martin White & Nancy J. Trapp
Jennifer Wise
Annelle Woggon
Richard & Maryann Zavadowski
Alyssa Zeller
Maggie Zeqiri
Dr. Susan E. Baer
Amy L. Barnett
Maxa Schutzbank Berid, Esq.
Debbie & Carl Berkowitz
Dr. John Cohee
Carol Davey
Jean & Steven Eichberg
Gregory Gest
Tom S. Lakritz
Debra & Michael Linick
Kimberly A. Metcalf
Lawrence Prager & Linda Myszak
Harris M. Sholman
Robert Werner
Anna M. White
The Mason Society honors those who support the Lymphoma Research Foundation’s (LRF) work through bequests or other planned gifts. Planned giving provides an important and long-term funding source that can be used to accelerate biomedical research and the development of new treatments now and in the future.
When you include the Lymphoma Research Foundation (LRF) in your estate plan, you are investing in the most promising research that has the greatest potential to dramatically improve the lives of those impacted by lymphoma.
Thank you for ensuring LRF can serve those touched by this disease well into the future and, ultimately, eradicate lymphoma.
To learn more, contact Kate LeBoeuf at (646) 531-5184 or kleboeuf@lymphoma.org, or visit lymphoma.org/legacy.
National Headquarters Wall Street Plaza 88 Pine Street, Suite 2400 New York, NY 10005
LRF Helpline (800) 500-9976
helpline@lymphoma.org lymphoma.org
